EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study

Pantelis Panagakis, Kanella Kalapothakou, Despina Exadactylou, Ioanna Lefaki, Marina Papoutsaki, Natalia Rompoti, Dimitrios Xekardakis, Nikolaos Fekkas, Efthymios Stathatos, Athanasios Chaniotis, Electra Nicolaidou, Alexandros Stratigos und 1 weitere

JEADV Clinical Practice · 11.08.2026

DOI: 10.1002/jvc2.70411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 11.08.2026. Verfasst von Pantelis Panagakis und 12 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a known risk factor for psoriasis and has been implicated in reduced effectiveness of certain biologic treatments. While most studies examine the role of body mass index (BMI), less is known about the impact of absolute body weight on brodalumab outcomes, particularly in real‐world settings.

Objectives

This study aimed to evaluate the association of baseline body weight and BMI with the clinical effectiveness and patient‐reported outcomes (PROs) of brodalumab in patients with moderate‐to‐severe plaque psoriasis.

Methods

A post hoc analysis of the RESOLVE study‐a prospective, multicenter, single‐arm real‐world study conducted in Greece‐was performed. A total of 145 patients initiating brodalumab were followed for 52 weeks. Clinical outcomes [Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA)] and PROs [Dermatology Life Quality Index (DLQI), Patient Global Assessment (PaGA), Treatment Satisfaction Questionnaire for Medication (TSQM‐9)] were compared across BMI categories and body weight groups (< 100 kg vs. ≥ 100 kg). Longitudinal population‐averaged models were used to assess longitudinal treatment responses.

Results

Patients ≥ 100 kg exhibited delayed clinical responses, with significantly lower PASI90, PASI100, and sPGA 0 rates at Weeks 24‐Weeks 52 compared to those < 100 kg. In contrast, BMI‐based differences were inconsistent. Generalized estimating equations (GEE) modeling showed significantly slower odds of achieving PASI ≤ 3 in the ≥ 100 kg group at Week 24, although long‐term improvement was observed in all patients. PROs revealed smaller early DLQI and TSQM‐9 improvements in heavier patients, though differences for TSQM‐9 resolved by Weeks 52. PaGA “free of symptoms” responses were also numerically lower in ≥ 100 kg patients early on, converging at 1 year.

Conclusions

The results demonstrated that a body weight threshold of ≥ 100 kg may be a more sensitive predictor than BMI for identifying psoriasis patients at risk of delayed or reduced brodalumab response. Thus, these findings may contribute to patient counselling and management.

Zitieren

APA

Panagakis, P., Kalapothakou, K., Exadactylou, D., Lefaki, I., Papoutsaki, M., Rompoti, N., Xekardakis, D., Fekkas, N., Stathatos, E., Chaniotis, A., Nicolaidou, E., Stratigos, A., & Chasapi, V. (2026). Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70411

Vancouver

Panagakis P, Kalapothakou K, Exadactylou D, Lefaki I, Papoutsaki M, Rompoti N, et al. Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70411

BibTeX
@article{Panagakis2026,
  author = {Panagakis, Pantelis and Kalapothakou, Kanella and Exadactylou, Despina and Lefaki, Ioanna and Papoutsaki, Marina and Rompoti, Natalia and Xekardakis, Dimitrios and Fekkas, Nikolaos and Stathatos, Efthymios and Chaniotis, Athanasios and Nicolaidou, Electra and Stratigos, Alexandros and Chasapi, Vasiliki},
  title = {Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study},
  journal = {JEADV Clinical Practice},
  year = {2026},
  doi = {10.1002/jvc2.70411}
}
Kostenlos starten →